Danaher Corporation
DHRHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeDanaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. At a $127.84B market cap, Danaher Corporation ranks as a large-cap company within healthcare. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
Market Cap
$127.84B
Beta
0.84
P/E (TTM)
34.94
P/E (Fwd)
19.86
EPS (TTM)
$5.17
EPS (Fwd)
$9.10
ROE
7.1%
ROA
4.2%
Cash
$5.70B
Total Debt
$19.68B
Free CF
$4.57B
52W Change
-4.9%
Annual Financials
Cash vs Debt
Danaher Corporation carries $19.68B in total debt against $5.70B in cash reserves — debt is roughly 3.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $4.57B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 7.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $26.64B (2022) to $24.57B (2025).
As with any equity investment, DHR carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Danaher Corporation's trajectory.